Nintedanib esylate

본문 바로가기


Home > Product > Nintedanib esylate
Selling leads
Nintedanib esylate
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Nintedanib sulfonate is a small molecule inhibitor of multi-receptor tyrosine kinases and non-receptor tyrosine kinases. It was first approved by the US FDA in 2014 and was first developed and sold by Boehringer Ingelheim. It has been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Agency for Medicines and Medical Devices (PMDA) for the treatment of idiopathic pulmonary fibrosis, and has also been approved by the EMA for non-small cell lung cancer.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top